The Use of Barbital Compounds in Producing Analgesia and Amnesia in Labor
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) United States Patent (10) Patent No.: US 8,124,126 B2 Bosse Et Al
USOO81241.26B2 (12) United States Patent (10) Patent No.: US 8,124,126 B2 BOSse et al. (45) Date of Patent: Feb. 28, 2012 (54) PHARMACEUTICAL COMPOSITIONS (58) Field of Classification Search ........................ None See application file for complete search history. (75) Inventors: Paul Bosse, Charleston, SC (US); John Ameling, Cincinnati, OH (US); Bernard (56) References Cited Schachtel, Jupiter, FL (US); Ray Takigiku, Loveland, OH (US) U.S. PATENT DOCUMENTS 4,113,866 A 9, 1978 Lednicer et al. (73) Assignee: Charleston Laboratories, Inc., (Continued) Charleston, SC (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this CA 2665841 10/2007 patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 12/351,704 OTHER PUBLICATIONS Alexander, etal. Comparison ofondansetron and droperidol in reduc (22) Filed: Jan. 9, 2009 ing postoperative nausea and vomiting associated with patient-con trolled analgesia. Anaesthesia. Dec. 1995:50(12): 1086-8. (65) Prior Publication Data (Continued) US 2009/O175939 A1 Jul. 9, 2009 Primary Examiner — Susan Tran Related U.S. Application Data (74) Attorney, Agent, or Firm — Wilson Sonsini Goodrich & (60) Provisional application No. 61/020,139, filed on Jan. Rosati 9, 2008, provisional application No. 61/043,037, filed on Apr. 7, 2008, provisional application No. (57) ABSTRACT 61/060,758, filed on Jun. 11, 2008. Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including (51) Int. Cl. reducing or eliminating an adverse effect associated with the A6 IK9/20 (2006.01) analgesic. A6 IK9/24 (2006.01) (52) U.S. -
Comparative Enhancing Effects of Phenobarbital, Amobarbital
[CANCER RESEARCH 35,2884 2890, October 1975] Comparative Enhancing Effects of Phenobarbital, Amobarbital, Diphenylhydantoin, and Dichlorodiphenyltrichloroethane on 2-Acetylaminofluorene-induced Hepatic Tumorigenesis in the Rat Carl Peraino, R. J. Michael Fry, Everett Staffeldt, and John P. Christopher 2 Division of Biological and Medical Research, Argonne National Laboratory, Argonne, Illinois 60439 SUMMARY INTRODUCTION Earlier studies showed that phenobarbital feeding en- In earlier studies (27, 29), the prolonged feeding of hanced hepatic tumorigenesis in rats previously fed 2- phenobarbital to rats that had previously been fed AAF 3 for acetylaminofluorene for a brief period. As part of an a brief period markedly increased the subsequent incidence investigation of the mechanism of this enhancement, the of liver tumors. Using this sequential feeding regime, the present study evaluated the relative enhancing abilities of present study evaluated the relative tumorigenic enhancing amobarbital, diphenylhydantoin, and dichlorodiphenyltri- abilities of other compounds that, to varying degrees, chloroethane (DDT), agents that resemble phenobarbital to resemble phenobarbital in their effects on liver structure and varying degrees in their effects on liver structure and metabolism. The substances examined were amobarbital, metabolism. A comparison of hepatic tumor yields in rats diphenylhydantoin, and DDT. Table 1 compares relevant fed 2-acetylaminofluorene, followed by the test substance characteristics of these agents with those of phenobarbital, (sequential treatment), showed that amobarbital and di- reviewed previously (27, 29). Amobarbital is closest to phenylhydantoin had no enhancing activity, whereas the phenobarbital in structure and, like phenobarbital, alters enhancing effect of DDT was similar to that of phenobarbi- the metabolism of other drugs by the liver. Diphenylhydan- tal. -
(12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter Et Al
USOO9205048B2 (12) United States Patent (10) Patent No.: US 9.205,048 B2 Lichter et al. (45) Date of Patent: *Dec. 8, 2015 (54) CONTROLLED RELEASE ANTIMICROBIAL (58) Field of Classification Search COMPOSITIONS AND METHODS FOR THE CPC A61 K9/0024; A61 K9/0046; A61K 31/497; TREATMENT OF OTC DSORDERS A61K 47/34 See application file for complete search history. (71) Applicants: Otonomy, Inc., San Diego, CA (US); The Regents of the University of California, Oakland, CA (US) (56) References Cited (72) Inventors: Jay Lichter, Rancho Santa Fe, CA (US); U.S. PATENT DOCUMENTS Andrew M. Trammel, Olathe, KS (US); 4,188,373 A 2, 1980 Krezanoski Fabrice Piu, San Diego, CA (US); 4,478,822 A 10, 1984 Haslam et al. Qiang Ye, San Diego, CA (US); Luis A. 4,938,763. A 7, 1990 Dunn et al. Dellamary, San Marcos, CA (US); Carl 4,968,507 A 11/1990 Zentner et al. 5,033,252 A 7, 1991 Carter Lebel, Malibu, CA (US); Jeffrey P. 5,052,558 A 10, 1991 Carter Harris, La Jolla, CA (US) 5,292,516 A 3/1994 Viegas et al. 5,323,907 A 6/1994 Kalvelage (73) Assignees: OTONOMY, INC., San Diego, CA 5,324,519 A 6/1994 Dunn et al. (US): THE REGENTS OF THE 5,421,818 A 6/1995 Arenberg UNIVERSITY OF CALIFORNLA, 5,474,529 A 12/1995 Arenberg 5,476,446 A 12/1995 Arenberg Oakland, CA (US) 5,503,848 A 4/1996 Perbellini et al. 5,702,716 A 12/1997 Dunn et al. -
Barbiturates for the Treatment of Alcohol Withdrawal Syndrome: ☆ a Systematic Review of Clinical Trials
Journal of Critical Care 32 (2016) 101–107 Contents lists available at ScienceDirect Journal of Critical Care journal homepage: www.jccjournal.org Barbiturates for the treatment of alcohol withdrawal syndrome: ☆ A systematic review of clinical trials Yoonsun Mo, MS, Pharm.D., BCPS, BCCCP a,b,⁎, Michael C. Thomas, Pharm.D., BCPS, FCCP a,1, George E. Karras Jr., MD, FCCM b,2 a Department of Pharmacy Practice, Western New England University College of Pharmacy, 1215 Wilbraham Road, Springfield, MA 01119 b Mercy Medical Center, 271 Carew Street, Springfield, MA 01104 article info abstract Keywords: Purpose: To perform a systematic review of the clinical trials concerning the use of barbiturates for the treatment Barbiturates of acute alcohol withdrawal syndrome (AWS). Phenobarbital Materials and Methods: A literature search of MEDLINE, EMBASE, and the Cochrane Library, together with a man- Benzodiazepines ual citation review was conducted. We selected English-language clinical trials (controlled and observational Alcohol withdrawal syndrome studies) evaluating the efficacy and safety of barbiturates compared with benzodiazepine (BZD) therapy for Delirium tremens Systematic review the treatment of AWS in the acute care setting. Data extracted from the included trials were duration of delirium, number of seizures, length of intensive care unit and hospital stay, cumulated doses of barbiturates and BZDs, and respiratory or cardiac complications. Results: Seven studies consisting of 4 prospective controlled and 3 retrospective trials were identified. Results from all the included studies suggest that barbiturates alone or in combination with BZDs are at least as effective as BZDs in the treatment of AWS. Furthermore, barbiturates appear to have acceptable tolerability and safety pro- files, which were similar to those of BZDs in patients with AWS. -
Original Article Effects of Repeated High Dosage of Chloral Hydrate and Pentobarbital Sodium Anesthesia on Hepatocellular System in Rats
Int J Clin Exp Med 2015;8(7):10568-10576 www.ijcem.com /ISSN:1940-5901/IJCEM0008402 Original Article Effects of repeated high dosage of chloral hydrate and pentobarbital sodium anesthesia on hepatocellular system in rats Jianhong Yu1*, Xuehui Sun2*, Guifeng Sang3 1Department of Anesthesiology, Yuhuangding Hospital, Yantai 264000, China; 2Department of Rheumatology, Yuhuangding Hospital, Yantai 264000, China; 3Operating Room, Yuhuangding Hospital, Yantai 264000, China. *Equal contributors. Received March 24, 2015; Accepted July 2, 2015; Epub July 15, 2015; Published July 30, 2015 Abstract: This study aims to investigate the possible effects of repeated high dosage of chloral hydrate and pen- tobarbital sodium anesthesia on hepatocellular system in rats. Thirty Sprague Dawley rats were randomly divided into 3 groups: control group (group A), chloral hydrate group (group B) and pentobarbital sodium group (group C). Antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione s transferase (GST) and catalase (CAT) activities and thiobarbituric acid-reactive substances (TBARS) level as well as serum biochemi- cal parameters alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (T-BIL) were determined. Liver histopathological examinations were performed at termination. Furthermore, Bax and Bcl-2 expression, and caspase-3 activity were also evaluated. The SOD, GSH-Px, GST and CAT activities significantly decreased but TBARS levels increased in group B and C compared with group A. Hepatic injury was evidenced by a significant increase in serum ALT, AST and ALP activities in group B and C, which also con- firmed by the histopathological alterations. Moreover, administration of chloral hydrate and pentobarbital sodium could induce certain hepatic apoptosis accompanied by the upregulated Bax expression, the downregulated Bcl-2 expression and Bcl-2/Bax ratio, and the increase of caspase-3 activity. -
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: an American Academy of Sleep Medicine Clinical Practice Guideline Michael J
pii: jc-00382-16 http://dx.doi.org/10.5664/jcsm.6470 SPECIAL ARTICLES Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline Michael J. Sateia, MD1; Daniel J. Buysse, MD2; Andrew D. Krystal, MD, MS3; David N. Neubauer, MD4; Jonathan L. Heald, MA5 1Geisel School of Medicine at Dartmouth, Hanover, NH; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of California, San Francisco, San Francisco, CA; 4Johns Hopkins University School of Medicine, Baltimore, MD; 5American Academy of Sleep Medicine, Darien, IL Introduction: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad classes of drugs, this guideline focuses on individual drugs commonly used to treat insomnia. It includes drugs that are FDA-approved for the treatment of insomnia, as well as several drugs commonly used to treat insomnia without an FDA indication for this condition. This guideline should be used in conjunction with other AASM guidelines on the evaluation and treatment of chronic insomnia in adults. Methods: The American Academy of Sleep Medicine commissioned a task force of four experts in sleep medicine. A systematic review was conducted to identify randomized controlled trials, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence. The task force developed recommendations and assigned strengths based on the quality of evidence, the balance of benefits and harms, and patient values and preferences. -
(12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al
USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al. -
Article on Relative Abuse Liability of Triazolam
Neuroscience & giobehaviora[Reviews. Vol. 9, pp. 133-151. 19_5. e Ankho International Inc. Printed in the U.S.A 0149-7634/85 5300 ÷ 00 Relative Abuse Liability of Triazolam: Experimental Assessment in Animals and Humans ROLAND R. GRIFFITHS,** RICHARD J. LAMB,* NANCY A. ATOR,* JOHN D. ROACHE* AND JOSEPH V. BRADY** Departments of *Psychiatry and tNeuroscience. The Johns Hopkins University School of Medicine 720 Rutland Avenue, Baltimore, MD 21205 GRIFFITHS, R. R., R. J. LAMB, N. A. ATOR, J. D. ROACHE AND J. V. BRADY. Relative abuse liability oftriazolam: Experimental assessment in animals and humans. NEUROSCI BIOBEHAV REV 9(1) 133--151. 1985.--The abuse liability of a drug is a positive, interactive function of the reinforcing and adverse effects of the drug. The relative abuse liability of the hypnotic henzodiazepine, triazoiam, has been controversial. This paper reviews animal and human studies beating on its relative abuse liability, including data on pharmacological profile, reinforcing effects, liking, speed of onset, discrimina- tive stimulus effects, subjective effects, physiological dependence, rebound and early morning insomnia, drug produced anxiety, lethality in overdose, psychomotor impairment, interactions with ethanol anterogr_e amnesia, impaired aware- ness of drug effect, and other psychiatric and behavioral disturbances. It is concluded that the abuse liability of triazolam is less than that of the intermediate duration barbiturates such as pentobarbital. Although there are considerable data indicating similarities of triazolam to other benzodiazepines, there is also substantial speculation among clinical inves- til_tors and some limited data suggesting that the abuse liability of triazolam is greater than that of a variety of other benzodiazepines, and virtually no credible data or speculation that it is less. -
Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87 -
Management of Drug and Alcohol Withdrawal
The new england journal of medicine review article current concepts Management of Drug and Alcohol Withdrawal Thomas R. Kosten, M.D., and Patrick G. O’Connor, M.D., M.P.H. From the Departments of Psychiatry (T.R.K.) ach year in the united states, approximately 8.2 million persons and Medicine (P.G.O.), Yale University are dependent on alcohol and 3.5 million are dependent on illicit drugs, includ- School of Medicine, New Haven, Conn.; e 1 and Veterans Affairs Connecticut Health- ing stimulants (1 million) and heroin (750,000). In a sample from primary care care System, West Haven, Conn. (T.R.K.). practice, 15 percent of patients had either an “at-risk” pattern of alcohol use or an alco- Address reprint requests to Dr. Kosten at hol-related health problem, and 5 percent had a history of illicit-drug use.2 With rates of Veterans Affairs Connecticut Healthcare System, Psychiatry 151D, 950 Campbell substance use so high, all patients should be carefully screened with validated instru- Ave., Bldg. 35, West Haven, CT 06516, or ments such as the CAGE questionnaire for alcohol dependence, which consists of the at [email protected]. following questions: Can you cut down on your drinking? Are you annoyed when asked N Engl J Med 2003;348:1786-95. to stop drinking? Do you feel guilty about your drinking? Do you need an eye-opener Copyright © 2003 Massachusetts Medical Society. drink when you get up in the morning? Physicians should be prepared to treat patients who have withdrawal syndromes.3 A carefully taken history should include the time of last use for each substance involved, and toxicologic screening should be performed to identify any additional substances used. -
Wo 2009/132050 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 29 October 2009 (29.10.2009) WO 2009/132050 A2 (51) International Patent Classification: 61/101,1 12 29 September 2008 (29.09.2008) US A61K 39/395 (2006.01) A61K 47/34 (2006.01) 61/140,033 22 December 2008 (22. 12.2008) US A61P 27/16 (2006.01) A61K 9/06 (2006.01) 61/160,233 13 March 2009 (13.03.2009) US (21) International Application Number: (71) Applicants (for all designated States except US): OTON- PCT/US2009/041320 OMY, INC. [US/US]; 5626 Oberlin Drive, Suite 100, San Diego, CA 92121 (US). THE REGENTS OF THE (22) International Filing Date: UNIVERSITY OF CALIFORNIA [US/US]; 1111 2 1 April 2009 (21 .04.2009) Franklin Street, 12th Floor, Oakland, CA 94607 (US). (25) Filing Language: English (72) Inventors; and (26) Publication Language: English (75) Inventors/Applicants (for US only): LICHTER, Jay [US/US]; P.O. Box 676244, Rancho Santa Fe, CA 92067 (30) Priority Data: (US). VOLLRATH, Benedikt [DE/US]; 4704 Niagara 61/046,543 2 1 April 2008 (21 .04.2008) US Avenue, San Diego, CA 92107 (US). TRAMMEL, An¬ 61/048,878 29 April 2008 (29.04.2008) US drew, M. [US/US]; 12485 South Alden Circle, Olathe, 61/127,7 13 14 May 2008 (14.05.2008) us KS 66062 (US). DURON, Sergio, G. [US/US]; 1605 61/055,625 23 May 2008 (23.05.2008) us Neale Street, San Diego, CA 92103 (US). -
Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, Mrna Levels, and Protein Expression Brittany T
University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 8-2016 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Brittany T. Wright University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Medicinal and Pharmaceutical Chemistry Commons, and the Neurosciences Commons Recommended Citation Wright, Brittany T. (http://orcid.org/0000-0002-1501-6596), "Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression" (2016). Theses and Dissertations (ETD). Paper 406. http://dx.doi.org/10.21007/ etd.cghs.2016.0408. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Neuroscience Research Advisor Scott A. Heldt, Ph.D. Committee Kristin M. Hamre, Ph.D. Michael P. McDonald, Ph.D. Kazuko Sakata, Ph.D. Jeffery D. Steketee, Ph.D. ORCID http://orcid.org/0000-0002-1501-6596 DOI 10.21007/etd.cghs.2016.0408 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/406 Repeated Zolpidem Treatment Effects on Sedative Tolerance, Withdrawal, mRNA Levels, and Protein Expression A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Brittany T.